Supplementary Figures and Tables from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421108

2023-01-01

Abstract:Supplementary figures and tables

What problem does this paper attempt to address?

Supplementary Data File 1 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421126.v1

2023-01-01

Abstract:Time vs. tumor volume plots for all 4,483 PDXs from PDXE dataset, generated using Xeva function plotPDX.
Supplementary Data File 3 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421120.v1

2023-01-01

Abstract:Pathway stability in PDXs across passages for Hallmark pathway set.
Supplementary Data File 5 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421114.v1

2023-01-01

Abstract:Analysis of drug response predicting biomarkers in PDXE dataset. For each tissue type and drug, association between genomic features (mutation copy number variation and gene expression) and drug response in PDXs are reported.
Supplementary Data File 6 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421111.v1

2023-01-01

Abstract:Association between drug class and pathways in PDXs. Drugs have been classified into categories according to their known target and association is computed using gene set enrichment analysis.
Supplementary Data File 4 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421117.v1

2023-01-01

Abstract:Pathway stability in PDXs across passages for Reactome pathway sets.
Supplementary Data File 2 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421123.v1

2023-01-01

Abstract:Intra-class correlation coefficient (ICC) values for genes across all samples and stratified by tissue type.
Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind Singh Mer,Wail Ba-alawi,Petr Smirnov,Yi Xiao Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1101/471227

IF: 11.2

2019-01-01

Cancer Research

Abstract:AbstractIdentifying robust biomarkers of drug response constitutes a key challenge in precision medicine. Patient-derived tumor xenografts (PDX) have emerged as reliable preclinical models that more accurately recapitulate tumor response to chemo- and targeted therapies. However, the lack of computational tools makes it difficult to analyze high-throughput molecular and pharmacologic profiles of PDX. We have developed Xenograft Visualization & Analysis (Xeva), an open-source software package for in vivo pharmacogenomic datasets that allows for quantification of variability in gene expression and pathway activity across PDX passages. We found that only a few genes and pathways exhibited passage-specific alterations and were therefore not suitable for biomarker discovery. Using the largest PDX pharmacogenomic dataset to date, we identified 87 pathways that are significantly associated with response to 51 drugs (FDR < 0.05). We found novel biomarkers based on gene expressions, copy number aberrations, and mutations predictive of drug response (concordance index > 0.60; FDR < 0.05). Our study demonstrates that Xeva provides a flexible platform for integrative analysis of preclinical in vivo pharmacogenomics data to identify biomarkers predictive of drug response, representing a major step forward in precision oncology.Significance:A computational platform for PDX data analysis reveals consistent gene and pathway activity across passages and confirms drug response prediction biomarkers in PDX.See related commentary by Meehan, p. 4324
Supplemental Material and Methods from an Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines

Julie Dutil,Zhihua Chen,Alvaro N.A. Monteiro,Jamie K. Teer,Steven Eschrich

DOI: https://doi.org/10.1158/0008-5472.22424004.v1

2023-01-01

Abstract:Supplemental Methods descriptions and supplemental references supporting this additional text.
Igmdr: Integrated Pharmacogenetic Resource Guide to Cancer Therapy and Research.

Xiang Chen,Yi Guo,Xin Chen

DOI: https://doi.org/10.1016/j.gpb.2019.11.011

IF: 6.409

2020-01-01

Genomics Proteomics & Bioinformatics

Abstract:Current pharmacogenetic studies have obtained many genetic models that can predict the therapeutic efficacy of anticancer drugs. Although some of these models are of crucial importance and have been used in clinical practice, these very valuable models have not been well adopted into cancer research to promote the development of cancer therapies due to the lack of integration and standards for the existing data of the pharmacogenetic studies. For this purpose, we built a resource investigating genetic model of drug response (iGMDR), which integrates the models from in vitro and in vivo pharmacogenetic studies with different omics data from a variety of technical systems. In this study, we introduced a standardized process for all integrations, and described how users can utilize these models to gain insights into cancer. iGMDR is freely accessible at https://igmdr.modellab.cn.
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Supplementary Tables and Figures from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators

Maarten Fornerod,Jing Ma,Sanne Noort,Yu Liu,Michael P. Walsh,Lei Shi,Stephanie Nance,Yanling Liu,Yuanyuan Wang,Guangchun Song,Tamara Lamprecht,John Easton,Heather L. Mulder,Donald Yergeau,Jacquelyn Myers,Jennifer L. Kamens,Esther A. Obeng,Martina Pigazzi,Marie Jarosova,Charikleia Kelaidi,Sophia Polychronopoulou,Jatinder K. Lamba,Sharyn D. Baker,Jeffrey E. Rubnitz,Dirk Reinhardt,Marry M. van den Heuvel-Eibrink,Franco Locatelli,Henrik Hasle,Jeffery M. Klco,James R. Downing,Jinghui Zhang,Stanley Pounds,C. Michel Zwaan,Tanja A. Gruber

DOI: https://doi.org/10.1158/2643-3230.22543719.v1

2023-01-01

Abstract:Supplementary Tables and Figures
Supplementary Table S1 and Figure Legends from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Clemens Krepler,Min Xiao,Katrin Sproesser,Patricia A. Brafford,Batool Shannan,Marilda Beqiri,Qin Liu,Wei Xu,Bradley Garman,Katherine L. Nathanson,Xiaowei Xu,Giorgos C. Karakousis,Gordon B. Mills,Yiling Lu,Tamer A. Ahmed,Poulikos I. Poulikakos,Giordano Caponigro,Markus Boehm,Malte Peters,Lynn M. Schuchter,Ashani T. Weeraratna,Meenhard Herlyn

DOI: https://doi.org/10.1158/1078-0432.22458780.v1

2023-01-01

Abstract:Supplementary Table S1: Summary of melanoma patients with clinical follow-up. Figure Legends
Supplemental Tables from Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer

Bohai Feng,Ying Shen,Xavier Pastor Hostench,Matthias Bieg,Michaela Plath,Naveed Ishaque,Roland Eils,Kolja Freier,Wilko Weichert,Karim Zaoui,Jochen Hess

DOI: https://doi.org/10.1158/1078-0432.22475567

2023-01-01

Abstract:<p>Supplemental Tables_revised</p>
Supplementary Materials from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Leo Zhang,Krystle Nomie,Hui Zhang,Taylor Bell,Lan Pham,Sabah Kadri,Jeremy Segal,Shaoying Li,Shouhao Zhou,David Santos,Shawana Richard,Shruti Sharma,Wendy Chen,Onyekachukwu Oriabure,Yang Liu,Shengjian Huang,Hui Guo,Zhihong Chen,Wenjing Tao,Carrie Li,Jack Wang,Bingliang Fang,Jacqueline Wang,Lei Li,Maria Badillo,Makhdum Ahmed,Selvi Thirumurthi,Steven Y. Huang,Yiping Shao,Laura Lam,Qing Yi,Y. Lynn Wang,Michael Wang

DOI: https://doi.org/10.1158/1078-0432.22467485.v1

2023-01-01

Abstract:Include supplementary Figure S1-S4 legends; Supplementary Table S1 and S4; and list Supplementary Table S2 and S3 titles. Supplementary Table S1. The panel of drugs used in vitro and in vivo with their doses and duration. Supplementary Table S4. The mean passage time per generation for 5 generations
Supplementary Table 1 from An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens as Potential Immunologic and Clinical Targets in Cancer

Qing-Wen Xu,Wei Zhao,Yue Wang,Maureen A. Sartor,Dong-Mei Han,Jixin Deng,Rakesh Ponnala,Jiang-Ying Yang,Qing-Yun Zhang,Guo-Qing Liao,Yi-Mei Qu,Lu Li,Fang-Fang Liu,Hong-Mei Zhao,Yan-Hui Yin,Wei-Feng Chen,Yu Zhang,Xiao-Song Wang

DOI: https://doi.org/10.1158/0008-5472.22394709

2023-01-01

Abstract:<p>PDF file - 66K, Detailed information for the adult somatic tissues and cancer tissues from the five Affymetrix U133 plus2 gene expression datasets compiled for HEPA analysis</p>
Supplementary Figure from Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies

Li Song,Zhangyi Ouyang,David Cohen,Yang Cao,Jennifer Altreuter,Gali Bai,Xihao Hu,Kenneth J. Livak,Heng Li,Ming Tang,Bo Li,X. Shirley Liu

DOI: https://doi.org/10.1158/2326-6066.22544670.v1

2023-01-01

Abstract:Supplementary Figure from Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies
Supplementary Tables and Figure from Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer

Filip Janků,Shile Zhang,Jill Waters,Li Liu,Helen J. Huang,Vivek Subbiah,David S. Hong,Daniel D. Karp,Siqing Fu,Xinjiang Cai,Nishma M. Ramzanali,Kiran Madwani,Goran Cabrilo,Debra L. Andrews,Yue Zhao,Milind Javle,E. Scott Kopetz,Rajyalakshmi Luthra,Hyunsung J. Kim,Sante Gnerre,Ravi Vijaya Satya,Han‐Yu Chuang,Kristina M. Kruglyak,Jonathan Toung,Zhao Chen,Richard Shen,John V. Heymach,Funda Meric‐Bernstam,Gordon B. Mills,Jian‐Bing Fan,Neeraj Salathia

DOI: https://doi.org/10.1158/1078-0432.22468095

2023-01-01

Abstract:Supplementary Tables and Figure
Supplementary Figure S5 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Clemens Krepler,Min Xiao,Katrin Sproesser,Patricia Brafford,Batool Shannan,Marilda Beqiri,Qin Liu,Xu Wang,Bradley Garman,Katherine L. Nathanson,Xiaowei Xu,Giorgos C. Karakousis,Gordon B. Mills,Yiling Lu,Tamer A. Ahmed,Poulikos I. Poulikakos,Giordano Caponigro,Markus Boehm,Malte L. Peters,Lynn M. Schuchter,Ashani T. Weeraratna,Meenhard Herlyn

DOI: https://doi.org/10.1158/1078-0432.22458789

2023-01-01

Abstract:A. heat map of complete RPPA data median centered, all tumor grafts untreated. Data are mean of 3 biological replicates, red is up, green is down. B. Principal component analysis (PCA) of median centered data C. heat map of fold change between untreated tumor grafts and on chronic BRAF inhibitor therapy. D. Principal component analysis (PCA) of fold change data.
Supplementary Data from Efficient Tumor Clearance and Diversified Immunity Through Neoepitope Vaccines and Combinatorial Immunotherapy

Karin L. Lee,Stephen C. Benz,Kristin C. Hicks,Andrew Nguyen,Sofia R. Gameiro,Claudia Palena,J. Zachary Sanborn,Zhen Su,Peter Ordentlich,Lars Rohlin,John H. Lee,Shahrooz Rabizadeh,Patrick Soon‐Shiong,Kayvan Niazi,Jeffrey Schlom,Duane H. Hamilton

DOI: https://doi.org/10.1158/2326-6066.22542444

2023-01-01

Abstract:Supplementary figures and tables
Supplementary Tables 1-3 from Integration of Host-Related Signatures with Cancer Cell–Derived Predictors for the Optimal Management of Anticancer Chemotherapy

Laurence Zitvogel,Oliver Kepp,Laetitia Aymeric,Yuting Ma,Clara Locher,Nicolas F. Delahaye,Fabrice André,Guido Kroemer

DOI: https://doi.org/10.1158/0008-5472.22385201

2023-01-01

Abstract:Supplementary Tables 1-3 from Integration of Host-Related Signatures with Cancer Cell–Derived Predictors for the Optimal Management of Anticancer Chemotherapy

Supplementary Figures and Tables from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 1 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 3 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 5 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 6 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 4 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 2 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplemental Material and Methods from an Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines

Igmdr: Integrated Pharmacogenetic Resource Guide to Cancer Therapy and Research.

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Tables and Figures from Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators

Supplementary Table S1 and Figure Legends from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Supplemental Tables from Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer

Supplementary Materials from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Supplementary Table 1 from An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens as Potential Immunologic and Clinical Targets in Cancer

Supplementary Figure from Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies

Supplementary Tables and Figure from Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer

Supplementary Figure S5 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Supplementary Data from Efficient Tumor Clearance and Diversified Immunity Through Neoepitope Vaccines and Combinatorial Immunotherapy

Supplementary Tables 1-3 from Integration of Host-Related Signatures with Cancer Cell–Derived Predictors for the Optimal Management of Anticancer Chemotherapy